157 related articles for article (PubMed ID: 36894309)
21. Effectiveness and acceptability of home use of misoprostol for medical abortion up to 10 weeks of pregnancy.
Podolskyi V; Gemzell-Danielsson K; Maltzman LL; Marions L
Acta Obstet Gynecol Scand; 2023 May; 102(5):541-548. PubMed ID: 36933004
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness and safety of early medication abortion provided in pharmacies by auxiliary nurse-midwives: A non-inferiority study in Nepal.
Rocca CH; Puri M; Shrestha P; Blum M; Maharjan D; Grossman D; Regmi K; Darney PD; Harper CC
PLoS One; 2018; 13(1):e0191174. PubMed ID: 29351313
[TBL] [Abstract][Full Text] [Related]
23. Safety, Efficacy and Acceptability of Early First Trimester Abortion using Oral Mifepristone and Sublingual Misoprostol.
Shrestha D; Aryal S; Sharma B
J Nepal Health Res Counc; 2018 Oct; 16(3):269-273. PubMed ID: 30455484
[TBL] [Abstract][Full Text] [Related]
24. A prospective open-label study of home use of mifepristone for medical abortion in Nepal.
Conkling K; Karki C; Tuladhar H; Bracken H; Winikoff B
Int J Gynaecol Obstet; 2015 Mar; 128(3):220-3. PubMed ID: 25482435
[TBL] [Abstract][Full Text] [Related]
25. Self-assessment of medical abortion outcome using symptoms and home pregnancy testing.
Raymond EG; Tan YL; Grant M; Benavides E; Reis M; Sacks DN; Hannum C; Frapp S; Weaver MA
Contraception; 2018 Apr; 97(4):324-328. PubMed ID: 29242085
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days.
Gatter M; Cleland K; Nucatola DL
Contraception; 2015 Apr; 91(4):269-73. PubMed ID: 25592080
[TBL] [Abstract][Full Text] [Related]
27. Mail-order pharmacy dispensing of mifepristone for medication abortion after in-person clinical assessment.
Grossman D; Raifman S; Morris N; Arena A; Bachrach L; Beaman J; Biggs MA; Hannum C; Ho S; Schwarz EB; Gold M
Contraception; 2022 Mar; 107():36-41. PubMed ID: 34555420
[TBL] [Abstract][Full Text] [Related]
28. Acceptability and feasibility of 400 μg buccal misoprostol after 200 mg mifepristone for early medical abortion in Georgia.
Tsereteli T; Chong E; Louie K; Bokhua Z; Winikoff B
Eur J Contracept Reprod Health Care; 2016 Oct; 21(5):367-71. PubMed ID: 27449873
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of self-managed medication abortion with accompaniment support in Argentina and Nigeria (SAFE): a prospective, observational cohort study and non-inferiority analysis with historical controls.
Moseson H; Jayaweera R; Egwuatu I; Grosso B; Kristianingrum IA; Nmezi S; Zurbriggen R; Motana R; Bercu C; Carbone S; Gerdts C
Lancet Glob Health; 2022 Jan; 10(1):e105-e113. PubMed ID: 34801131
[TBL] [Abstract][Full Text] [Related]
30. A telemedicine model for abortion in South Africa: a randomised, controlled, non-inferiority trial.
Endler M; Petro G; Gemzell Danielsson K; Grossman D; Gomperts R; Weinryb M; Constant D
Lancet; 2022 Aug; 400(10353):670-679. PubMed ID: 36030811
[TBL] [Abstract][Full Text] [Related]
31. A prospective, non-randomized study of home use of mifepristone for medical abortion in the U.S.
Chong E; Frye LJ; Castle J; Dean G; Kuehl L; Winikoff B
Contraception; 2015 Sep; 92(3):215-9. PubMed ID: 26142620
[TBL] [Abstract][Full Text] [Related]
32. Low-dose mifepristone followed by vaginal misoprostol at 48 hours for abortion up to 63 days.
Schaff EA; Fielding SL; Eisinger SH; Stadalius LS; Fuller L
Contraception; 2000 Jan; 61(1):41-6. PubMed ID: 10745068
[TBL] [Abstract][Full Text] [Related]
33. Feasibility, efficacy, safety, and acceptability of mifepristone-misoprostol for medical abortion in the Democratic People's Republic of Korea.
Tran NT; Jang MC; Choe YS; Ko WS; Pyo HS; Kim OS
Int J Gynaecol Obstet; 2010 Jun; 109(3):209-12. PubMed ID: 20206354
[TBL] [Abstract][Full Text] [Related]
34. Safety, efficacy, and acceptability of medical abortion in China, Cuba, and India: a comparative trial of mifepristone-misoprostol versus surgical abortion.
Winikoff B; Sivin I; Coyaji KJ; Cabezas E; Xiao B; Gu S; Du MK; Krishna UR; Eschen A; Ellertson C
Am J Obstet Gynecol; 1997 Feb; 176(2):431-7. PubMed ID: 9065194
[TBL] [Abstract][Full Text] [Related]
35. Self-administered multi-level pregnancy tests in simplified follow-up of medical abortion in Tunisia.
Dabash R; Shochet T; Hajri S; Chelli H; Hassairi AE; Haleb D; Labassi H; Sfar E; Temimi F; Koenig L; Winikoff B
BMC Womens Health; 2016 Jul; 16():49. PubMed ID: 27475998
[TBL] [Abstract][Full Text] [Related]
36. Medical methods for first trimester abortion.
Kulier R; Gülmezoglu AM; Hofmeyr GJ; Cheng LN; Campana A
Cochrane Database Syst Rev; 2004; (2):CD002855. PubMed ID: 15106180
[TBL] [Abstract][Full Text] [Related]
37. Medical methods for first trimester abortion.
Kulier R; Gülmezoglu AM; Hofmeyr GJ; Cheng LN; Campana A
Cochrane Database Syst Rev; 2004; (1):CD002855. PubMed ID: 14973995
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of mifepristone-buccal misoprostol for early medical abortion in an Australian clinical setting.
Goldstone P; Walker C; Hawtin K
Aust N Z J Obstet Gynaecol; 2017 Jun; 57(3):366-371. PubMed ID: 28303569
[TBL] [Abstract][Full Text] [Related]
39. Medical methods for first trimester abortion.
Kulier R; Kapp N; Gülmezoglu AM; Hofmeyr GJ; Cheng L; Campana A
Cochrane Database Syst Rev; 2011 Nov; 2011(11):CD002855. PubMed ID: 22071804
[TBL] [Abstract][Full Text] [Related]
40. Acceptability and feasibility of the use of 400 μg of sublingual misoprostol after mifepristone for medical abortion up to 63 days since the last menstrual period: evidence from Uzbekistan.
Raghavan S; Tsereteli T; Kamilov A; Kurbanbekova D; Yusupov D; Kasimova F; Jymagylova D; Winikoff B
Eur J Contracept Reprod Health Care; 2013 Apr; 18(2):104-11. PubMed ID: 23387475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
